Open AccessA systematic review and meta-analysis of the safety and efficacy of anti-thymocyte globulin combined with eltrombopag in the treatment of severe aplastic anemia
Author(s) -
Jiayou Zhang,
Yabing Wu,
Junhui Liu,
Shaolin Han,
Lijuan Chen,
Hui Wang,
Peng Yu
Publication year - 2021
Publication title -
annals of palliative medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.546
H-Index - 19
eISSN - 2224-5839
pISSN - 2224-5820
DOI - 10.21037/apm-21-1049
Subject(s) - eltrombopag , medicine , aplastic anemia , anti thymocyte globulin , odds ratio , randomized controlled trial , hazard ratio , meta analysis , gastroenterology , anemia , confidence interval , globulin , surgery , bone marrow , platelet , immune thrombocytopenia
When it comes to the treatment of aplastic anemia fever, the Guidelines for Aplastic Anemia regards Anti-thymocyte globulin (ATG) combined with eltrombopag as the standard immunosuppressive treatment plan, and ATG is the main mode to treat severe aplastic anemia. A large number of prospective studies and clinical trials have confirmed the clinical application value of eltrombopag in aplastic anemia. Although ATG combined with eltrombopag brings satisfactory treatment results, the safety of long-term use is still unclear. Therefore, more clinical trial studies are needed to verify its safety.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom